Forskning ved Københavns Universitet - Københavns Universitet

Forside

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Klaus Bendtzen
  • Pierre Geborek
  • Morten Svenson
  • Lotta Larsson
  • Meliha C Kapetanovic
  • Tore Saxne
Infliximab, an anti-tumor necrosis factor alpha (anti-TNFalpha) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be beneficial. This study was undertaken to investigate whether serologic monitoring of infliximab bioavailability and immunogenicity in individual patients would be useful in optimizing treatment regimens to improve efficacy and tolerability.
OriginalsprogEngelsk
TidsskriftArthritis & Rheumatism
Vol/bind54
Udgave nummer12
Sider (fra-til)3782-9
Antal sider8
ISSN0004-3591
DOI
StatusUdgivet - 1 dec. 2006

ID: 34102407